A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate
Phase of Trial: Phase IV
Latest Information Update: 25 Mar 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma Europe Ltd
- 31 Aug 2018 Biomarkers information updated
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 This trial has been completed in Germany according to European Clinical Trials Database record.